HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA transition team

This article was originally published in The Rose Sheet

Executive Summary

Senior Associate Commissioner Linda Suydam and two agency officials will act as points of contact during transition to new Administration, FDA announces. Suydam served as special assistant to then-Deputy Commissioner for Operations Jane Henney, MD, during the 1992 transition to the Clinton Administration and returned to the agency when Henney was named commissioner in 1998. She will be joined on the 2000 transition team by Senior Associate Commissioner for Policy, Planning & Legislation William Hubbard and Executive Secretary Catherine Beck. As is customary, HHS asked FDA to prepare briefing materials for review by the new Administration. Aside from a potential new commissioner, there likely will be little change in turnover at FDA directly related to the transition
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS008701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel